Dronedarone: Emergence of a New Therapeutic Option for the Treatment of Atrial Fibrillation

doi:10.1310/hpj4407-562

Abstract

This continuing feature updates readers on recent developments in cardiovascular pharmacotherapy. Cardiovascular disease remains the number 1 killer in the United States, and more clinical outcome trials have been conducted in cardiology than in any other field of medicine. Given this rapidly expanding knowledge base, if pharmacists stay current with developments in drug therapy, they can have a significant impact on prevention and treatment.

Authors

Institutions

No ROR-resolved institution is linked to this work yet.

Provenance

crossref

Confidence 100%

unpaywall

Confidence 95%

datacite

Confidence 0%

Referenced works

View all references →

No local reference links have been materialized yet.

Cited by

View all cited-by records →

No local citing links have been materialized yet.

External reference records

10.1016/j.amjcard.2008.06.025

10.1001/archinte.1995.00430050045005

10.1001/jama.285.18.2370

10.1378/chest.08-0678

Unresolved referenced work

2006

10.1016/s0140-6736(00)03230-x

10.1056/nejmoa021328

10.1056/nejmoa021375

10.1016/s0735-1097(03)00332-2

10.1056/nejm198702193160807

10.1177/106002809603000612

10.1001/jama.298.11.1312

Dronedarone: Emergence of a New Therapeutic Option for the Treatment of Atrial Fibrillation

Referenced works

Cited by

External reference records

Additional external references